Capricor Therapeutics presents results from HOPE-2 extension study

Capricor Therapeutics announced that the Company will present the positive 24-month results from its HOPE-2 open-label extension study with lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy at this year’s MDA Clinical and Scientific Conference which is taking place in Orlando, Florida from March 3-6, 2024. Key results from the study, include: Skeletal muscle function as measured by the Performance of the Upper Limb showed a mean PUL v2.0 decline after 24-months of treatment with CAP-1002 was 2.8 points versus a 7.7 point decline on average observed over 24-months in the placebo patient group. CAP-1002 revealed clinically meaningful improvements in ameliorating cardiac function.CAP-1002 treatment during the OLE portion of the study continues to yield a consistent favorable safety profile and has been well-tolerated throughout the study. The HOPE-2 OLE study previously met the primary endpoint at the one-year time-point and these 24-month results suggest that patients accumulate benefit over time with preservation of skeletal muscle function, which underscore the potential long-term benefit of CAP-1002